Prolight announces preliminary outcome of the rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Annual general meeting of Prolight Diagnostics AB (publ) on 30 June 2025
The annual general meeting (AGM) of Prolight Diagnostics AB (publ) took place on 30 June 2025 in Lund. Full information regarding the decisions of the AGM is available on the company’s website, www.prolightdx.com. The AGM resolved in accordance with all of the motions presented in the notification of the AGM. Resolution regarding the adoption of […]
Prolight Diagnostics showcases Psyros™ at ADLM 2025 in Chicago
Prolight Diagnostics AB will display a fully functioning commercial prototype of its groundbreaking Psyros Digital point of care IVD platform at the Association for Diagnostics & Laboratory Medicine (ADLM) 2025, in Chicago July 27th–29th. This marks the first public display of the company’s fully functioning Psyros™ prototype, developed to deliver rapid, lab-quality results at the […]
The last day of trading in subscription rights in Prolight’s rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]
Prolight announces additional subscription commitments from the board, management and existing shareholders
Prolight Diagnostics (“Prolight” or the “Company”) is pleased to announce that additional subscription commitments have been received from the Company’s board of directors and management in the ongoing rights issue of shares that Prolight resolved on, following approval from the subsequent extraordinary general meeting, on May 21, 2025 (the “Rights Issue”). The Company’s nominated Chairman […]
Prolight announces appointment of Professor Matt Reed to Clinical Advisory Board
Prolight Diagnostics announces today that Matt Reed, Professor of Emergency Medicine at Edinburgh University, will join the Clinical Advisory Board of the company. His appointment will bring additional insights into the implementation of point-of-care testing in the Emergency Department setting. “We are delighted to welcome Professor Reed onto our Clinical Advisory Board. It is important […]
Emergers publishes updated analysis for Prolight Diagnostics
Emergers updates analysis of Prolight Diagnostics following positive results from the whole blood study at St Thomas’ Hospital. Read the article here: https://www.emergers.se/prolight-k25/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing […]
Prolight invites to digital investor meeting due to recent achieved milestones
In connection with the subscription period for Prolight Diagnostics AB’s (Prolight’ or the ‘Company’) rights issue of shares, which runs between June 16 and June 30, 2025, the Company invites shareholders and external investors to a digital investor meeting. The meeting will be held via Microsoft Teams on June 24, 2025, at 14:00 CEST. During […]
Prolight receives notice of allowance in Japan for core patent related to Psyros™ technology
Prolight Diagnostics announces today that the company have received a notice of allowance from the Japanese Patent office for their primary patent application related to the Psyros single-molecule-counting technology. This is the second territory to allow this application, following grant by the European Patent Office earlier this year. “We are delighted to have another territory […]
The subscription period in Prolights rights issue of shares starts today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]
